Award recordCONTRACT

MERCK SHARP & DOHME LLC

PIID VA69D13J0039· VHA· 69D-NETWORK CONTRACT OFFICE 12· 6505 · DRUGS AND BIOLOGICALS· FY2013· $91,632 net obligations· UEI FCFDA78HKKG2· NJ

Description

ETONOGESTREL 68MG IMPLANT NEXPLANON(R) DEOBLIGATE REMAINING FUNDS DUE TO PROMPT PAYMENT DISCOUNT OF 2% AND CLOSE OUT PURCHASE ORDER.

Base award description: IGF::OT::IGF ETONOGESTREL 68MG IMPLANT NEXPLANON(R)

First action · last action
2013-01-10 · 2013-02-04
Transactions
2
First transaction's obligation
$93,502
Base + all options value (sum of deltas)
$91,632
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D30047
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$93,502$0Base award · 2013-01-10 · this action $93,502 · running total $93,502Modification P00001 · 2013-02-04 · this action -$1,870 · running total $91,632
  • Base2013-01-10+$93,502= $93,502
  • Mod P000012013-02-04-$1,870= $91,632
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2013-01-10+$93,502$93,502IGF::OT::IGF ETONOGESTREL 68MG IMPLANT NEXPLANON(R)
Mod P00001· CLOSE OUT2013-02-04−$1,870$91,632ETONOGESTREL 68MG IMPLANT NEXPLANON(R) DEOBLIGATE REMAINING FUNDS DUE TO PROMPT PAYMENT DISCOUNT OF 2% AND CLO…

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI FCFDA78HKKG2)

AwardOffice · PSC / listingNet obligationsFY
36C24526N0671245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$22,508FY2026
36C24526N0647245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$22,508FY2026
36C24526N0664245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$22,508FY2026
36C24526N0596245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$22,508FY2026
36C24526N0578245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$22,508FY2026
36C26026F0282260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$342,254FY2026

Other recipients under 6505 from 69D-NETWORK CONTRACT OFFICE 12 (most recent first)

AwardRecipientOfficeNet obligationsFY
VA69D16F2903CSL BEHRING L.L.C.69D-NETWORK CONTRACT OFFICE 12$5,443FY2016
VA69D16F2824SANOFI VACCINES US INC.69D-NETWORK CONTRACT OFFICE 12$53,837FY2016
VA69D16F2687SEQIRUS USA INC69D-NETWORK CONTRACT OFFICE 12$54,563FY2016
VA69D16F2660SEQIRUS USA INC69D-NETWORK CONTRACT OFFICE 12$125,000FY2016
VA69D16F2665GRIFOLS THERAPEUTICS LLC69D-NETWORK CONTRACT OFFICE 12$5,386FY2016

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA69D13J0039_3600_V797D30047_3600 · retrieved 2026-09-26.